<DOC>
	<DOCNO>NCT00612794</DOCNO>
	<brief_summary>Exenatide twice daily study Japanese type 2 diabetes patient . A once-weekly version exenatide currently evaluate . Study GWBW first study exenatide weekly Japanese patient . This study design evaluate safety tolerability exenatide weekly Japanese patient determine whether dose select US European development appropriate Japanese patient Type 2 diabetes .</brief_summary>
	<brief_title>A Study Examine Safety , Tolerability , Pharmacokinetics Pharmacodynamics Exenatide Once Weekly Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Body weight ≥50 kg . Have suboptimal glycemic control evidence HbA1c define follow criterion : *6.5 % 10.0 % , inclusive , study start patient manage diet modification exercise treat oral antidiabetic drug alpha glucosidase inhibitor meglitinide derivative ; *6.5 % 9.5 % , inclusive , study start patient treat oral antidiabetic include alpha glucosidase inhibitor meglitinide derivative . Have treat diet modification exercise alone combination stable regimen oral antidiabetic drug ( sulfonylurea , metformin thiazolidinedione ) least 2 month prior study start . In case patient concomitant use sulfonylurea , dose sulfonylurea must maximum recommended dose . The patient concomitant use alpha glucosidase inhibitor ( Glucobay® [ acarbose ] , Basen® [ voglibose ] , Seibule® [ miglitol ] ) meglitinide derivative ( Glufast® [ mitiglinide ] Fastic®/Starsis® [ nateglinide ] ) include study , drug must discontinue confirmation eligibility study start . Subjects donate 200 mL blood component blood donation within one month study start , donate 400 mL blood within three month study start . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have participate receive least one dose exenatide GLP1 analog study previously , study use exenatide GLP1 analog . Are treat exogenous insulin within 3 month screen . Are continuously treat follow excluded medication within 3 month screen ( 7 day per 1 month ) : *Drugs directly affect gastrointestinal motility , include Nauzelin® ( domperidone ) , Primperan®/Terperan® ( metoclopramide ) , Ganaton® ( itopride ) , Acenalin® ( cisapride ) , Gasmotin® ( mosapride ) , Cerekinon® ( trimebutine ) . Females breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>